Review



cell lines pl21  (DSMZ)


Bioz Verified Symbol DSMZ is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    DSMZ cell lines pl21
    Figure 1. NKCEs redirect NK cells to kill target cells with minimal cytokine release (A) Design of tool molecules NCR1xHER2 (NKCE) and CD3xHER2 (TCE). (B) HER2 expression on JIMT1-Luc WT and HER2−/−. Antibodies bound per cell (ABCs) of HER2 are indicated in the graph. (C and D) JIMT1-Luc WT and HER2−/−were incubated with NK cells or Pan T cells at an E:T cell ratio of 5:1 and increasing concentrations of NCR1xHER2 or CD3xHER2. (C) JIMT1-Luc cell lysis at 24 h; concentrations of TNF and IFNγ (D) in the cell culture supernatants at 24 h. (E) Design of tool molecules NCR1xCLL1 (NKCE-I) and CD3xCLL1 (huCLL1 TCE). (F) CLL1 expression on <t>PL21-Luc,</t> NOMO1-Luc, and MOLM13-Luc. ABC of CLL1 is indicated in the graph. (G and H) PL21-Luc, NOMO1-Luc, and MOLM13-Luc were incubated with NK cells or Pan T cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-I or huCLL1 TCE. (G) Target cell lysis at 48 h; (H) concentrations of TNF in the cell culture supernatants at 48 h. Data are presented as means ± SEM (C). The data shown are representative of at least two independent experiments.
    Cell Lines Pl21, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 35 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell lines pl21/product/DSMZ
    Average 94 stars, based on 35 article reviews
    cell lines pl21 - by Bioz Stars, 2026-03
    94/100 stars

    Images

    1) Product Images from "Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses."

    Article Title: Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses.

    Journal: Cell reports. Medicine

    doi: 10.1016/j.xcrm.2025.102117

    Figure 1. NKCEs redirect NK cells to kill target cells with minimal cytokine release (A) Design of tool molecules NCR1xHER2 (NKCE) and CD3xHER2 (TCE). (B) HER2 expression on JIMT1-Luc WT and HER2−/−. Antibodies bound per cell (ABCs) of HER2 are indicated in the graph. (C and D) JIMT1-Luc WT and HER2−/−were incubated with NK cells or Pan T cells at an E:T cell ratio of 5:1 and increasing concentrations of NCR1xHER2 or CD3xHER2. (C) JIMT1-Luc cell lysis at 24 h; concentrations of TNF and IFNγ (D) in the cell culture supernatants at 24 h. (E) Design of tool molecules NCR1xCLL1 (NKCE-I) and CD3xCLL1 (huCLL1 TCE). (F) CLL1 expression on PL21-Luc, NOMO1-Luc, and MOLM13-Luc. ABC of CLL1 is indicated in the graph. (G and H) PL21-Luc, NOMO1-Luc, and MOLM13-Luc were incubated with NK cells or Pan T cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-I or huCLL1 TCE. (G) Target cell lysis at 48 h; (H) concentrations of TNF in the cell culture supernatants at 48 h. Data are presented as means ± SEM (C). The data shown are representative of at least two independent experiments.
    Figure Legend Snippet: Figure 1. NKCEs redirect NK cells to kill target cells with minimal cytokine release (A) Design of tool molecules NCR1xHER2 (NKCE) and CD3xHER2 (TCE). (B) HER2 expression on JIMT1-Luc WT and HER2−/−. Antibodies bound per cell (ABCs) of HER2 are indicated in the graph. (C and D) JIMT1-Luc WT and HER2−/−were incubated with NK cells or Pan T cells at an E:T cell ratio of 5:1 and increasing concentrations of NCR1xHER2 or CD3xHER2. (C) JIMT1-Luc cell lysis at 24 h; concentrations of TNF and IFNγ (D) in the cell culture supernatants at 24 h. (E) Design of tool molecules NCR1xCLL1 (NKCE-I) and CD3xCLL1 (huCLL1 TCE). (F) CLL1 expression on PL21-Luc, NOMO1-Luc, and MOLM13-Luc. ABC of CLL1 is indicated in the graph. (G and H) PL21-Luc, NOMO1-Luc, and MOLM13-Luc were incubated with NK cells or Pan T cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-I or huCLL1 TCE. (G) Target cell lysis at 48 h; (H) concentrations of TNF in the cell culture supernatants at 48 h. Data are presented as means ± SEM (C). The data shown are representative of at least two independent experiments.

    Techniques Used: Expressing, Incubation, Lysis, Cell Culture

    Figure 3. Multiple functional NKCEs induce robust killing activity with minimal TNF production (A) Components and designs of multifunctional NKCEs: NKCE-I to NKCE-V. (B–D) NOMO1-Luc cells were incubated with NK cells or Pan T cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-I to NKCE-V and IL-2 or TCE. (B) NOMO1-Luc lysis at 48 h. EC50 and area under curve (AUC) are indicated in the graph. Concentrations of TNF (C) and IFNγ (D) in the cell culture su- pernatants at 48 h. (E) CLL1 expression on PL21-Luc WT and CLL1low. ABC of CLL1 is indicated in the graph. (F–H) PL21-Luc WT or CLL1low cells were incubated with NK cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-III (F), NKCE-IV (G), and NKCE-V (H) and PL21-Luc lysis at 48 h. Data are presented as means ± SEM (B). The data shown are representative of at least two independent experiments.
    Figure Legend Snippet: Figure 3. Multiple functional NKCEs induce robust killing activity with minimal TNF production (A) Components and designs of multifunctional NKCEs: NKCE-I to NKCE-V. (B–D) NOMO1-Luc cells were incubated with NK cells or Pan T cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-I to NKCE-V and IL-2 or TCE. (B) NOMO1-Luc lysis at 48 h. EC50 and area under curve (AUC) are indicated in the graph. Concentrations of TNF (C) and IFNγ (D) in the cell culture su- pernatants at 48 h. (E) CLL1 expression on PL21-Luc WT and CLL1low. ABC of CLL1 is indicated in the graph. (F–H) PL21-Luc WT or CLL1low cells were incubated with NK cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-III (F), NKCE-IV (G), and NKCE-V (H) and PL21-Luc lysis at 48 h. Data are presented as means ± SEM (B). The data shown are representative of at least two independent experiments.

    Techniques Used: Functional Assay, Activity Assay, Incubation, Lysis, Cell Culture, Expressing



    Similar Products

    cell lines pl21  (DSMZ)
    94
    DSMZ cell lines pl21
    Figure 1. NKCEs redirect NK cells to kill target cells with minimal cytokine release (A) Design of tool molecules NCR1xHER2 (NKCE) and CD3xHER2 (TCE). (B) HER2 expression on JIMT1-Luc WT and HER2−/−. Antibodies bound per cell (ABCs) of HER2 are indicated in the graph. (C and D) JIMT1-Luc WT and HER2−/−were incubated with NK cells or Pan T cells at an E:T cell ratio of 5:1 and increasing concentrations of NCR1xHER2 or CD3xHER2. (C) JIMT1-Luc cell lysis at 24 h; concentrations of TNF and IFNγ (D) in the cell culture supernatants at 24 h. (E) Design of tool molecules NCR1xCLL1 (NKCE-I) and CD3xCLL1 (huCLL1 TCE). (F) CLL1 expression on <t>PL21-Luc,</t> NOMO1-Luc, and MOLM13-Luc. ABC of CLL1 is indicated in the graph. (G and H) PL21-Luc, NOMO1-Luc, and MOLM13-Luc were incubated with NK cells or Pan T cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-I or huCLL1 TCE. (G) Target cell lysis at 48 h; (H) concentrations of TNF in the cell culture supernatants at 48 h. Data are presented as means ± SEM (C). The data shown are representative of at least two independent experiments.
    Cell Lines Pl21, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell lines pl21/product/DSMZ
    Average 94 stars, based on 1 article reviews
    cell lines pl21 - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    cell line pl21 acc 536  (DSMZ)
    90
    DSMZ cell line pl21 acc 536
    Figure 1. NKCEs redirect NK cells to kill target cells with minimal cytokine release (A) Design of tool molecules NCR1xHER2 (NKCE) and CD3xHER2 (TCE). (B) HER2 expression on JIMT1-Luc WT and HER2−/−. Antibodies bound per cell (ABCs) of HER2 are indicated in the graph. (C and D) JIMT1-Luc WT and HER2−/−were incubated with NK cells or Pan T cells at an E:T cell ratio of 5:1 and increasing concentrations of NCR1xHER2 or CD3xHER2. (C) JIMT1-Luc cell lysis at 24 h; concentrations of TNF and IFNγ (D) in the cell culture supernatants at 24 h. (E) Design of tool molecules NCR1xCLL1 (NKCE-I) and CD3xCLL1 (huCLL1 TCE). (F) CLL1 expression on <t>PL21-Luc,</t> NOMO1-Luc, and MOLM13-Luc. ABC of CLL1 is indicated in the graph. (G and H) PL21-Luc, NOMO1-Luc, and MOLM13-Luc were incubated with NK cells or Pan T cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-I or huCLL1 TCE. (G) Target cell lysis at 48 h; (H) concentrations of TNF in the cell culture supernatants at 48 h. Data are presented as means ± SEM (C). The data shown are representative of at least two independent experiments.
    Cell Line Pl21 Acc 536, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell line pl21 acc 536/product/DSMZ
    Average 90 stars, based on 1 article reviews
    cell line pl21 acc 536 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    pl21 cell lines  (DSMZ)
    93
    DSMZ pl21 cell lines
    Antiproliferative activities of CDDD11-8 against leukemia <t> cell lines </t> having different genetic backgrounds *.
    Pl21 Cell Lines, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pl21 cell lines/product/DSMZ
    Average 93 stars, based on 1 article reviews
    pl21 cell lines - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    pl21 aml cell lines  (DSMZ)
    93
    DSMZ pl21 aml cell lines
    Antiproliferative activities of CDDD11-8 against leukemia <t> cell lines </t> having different genetic backgrounds *.
    Pl21 Aml Cell Lines, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pl21 aml cell lines/product/DSMZ
    Average 93 stars, based on 1 article reviews
    pl21 aml cell lines - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    pl21 cell line  (Johns Hopkins HealthCare)
    90
    Johns Hopkins HealthCare pl21 cell line
    Antiproliferative activities of CDDD11-8 against leukemia <t> cell lines </t> having different genetic backgrounds *.
    Pl21 Cell Line, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pl21 cell line/product/Johns Hopkins HealthCare
    Average 90 stars, based on 1 article reviews
    pl21 cell line - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. NKCEs redirect NK cells to kill target cells with minimal cytokine release (A) Design of tool molecules NCR1xHER2 (NKCE) and CD3xHER2 (TCE). (B) HER2 expression on JIMT1-Luc WT and HER2−/−. Antibodies bound per cell (ABCs) of HER2 are indicated in the graph. (C and D) JIMT1-Luc WT and HER2−/−were incubated with NK cells or Pan T cells at an E:T cell ratio of 5:1 and increasing concentrations of NCR1xHER2 or CD3xHER2. (C) JIMT1-Luc cell lysis at 24 h; concentrations of TNF and IFNγ (D) in the cell culture supernatants at 24 h. (E) Design of tool molecules NCR1xCLL1 (NKCE-I) and CD3xCLL1 (huCLL1 TCE). (F) CLL1 expression on PL21-Luc, NOMO1-Luc, and MOLM13-Luc. ABC of CLL1 is indicated in the graph. (G and H) PL21-Luc, NOMO1-Luc, and MOLM13-Luc were incubated with NK cells or Pan T cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-I or huCLL1 TCE. (G) Target cell lysis at 48 h; (H) concentrations of TNF in the cell culture supernatants at 48 h. Data are presented as means ± SEM (C). The data shown are representative of at least two independent experiments.

    Journal: Cell reports. Medicine

    Article Title: Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses.

    doi: 10.1016/j.xcrm.2025.102117

    Figure Lengend Snippet: Figure 1. NKCEs redirect NK cells to kill target cells with minimal cytokine release (A) Design of tool molecules NCR1xHER2 (NKCE) and CD3xHER2 (TCE). (B) HER2 expression on JIMT1-Luc WT and HER2−/−. Antibodies bound per cell (ABCs) of HER2 are indicated in the graph. (C and D) JIMT1-Luc WT and HER2−/−were incubated with NK cells or Pan T cells at an E:T cell ratio of 5:1 and increasing concentrations of NCR1xHER2 or CD3xHER2. (C) JIMT1-Luc cell lysis at 24 h; concentrations of TNF and IFNγ (D) in the cell culture supernatants at 24 h. (E) Design of tool molecules NCR1xCLL1 (NKCE-I) and CD3xCLL1 (huCLL1 TCE). (F) CLL1 expression on PL21-Luc, NOMO1-Luc, and MOLM13-Luc. ABC of CLL1 is indicated in the graph. (G and H) PL21-Luc, NOMO1-Luc, and MOLM13-Luc were incubated with NK cells or Pan T cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-I or huCLL1 TCE. (G) Target cell lysis at 48 h; (H) concentrations of TNF in the cell culture supernatants at 48 h. Data are presented as means ± SEM (C). The data shown are representative of at least two independent experiments.

    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER muCD19 NKCE Amgen Inc In this paper muIgG-IL-2 Amgen Inc In this paper Critical commercial assays EasySepTM Human NK Cell Enrichment Kit STEMCELL Technologies Cat#19055 EasySepTM Human T cell Enrichment Kit STEMCELL Technologies Cat# 19051 EasySepTM Human CD4+ T cell Enrichment Kit STEMCELL Technologies Cat# 19052 EasySepTM Human CD8+ T cell Enrichment Kit STEMCELL Technologies Cat # 19053 Steady-Glo Luciferase Assay System Promega Cat# E2550 CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7573 CountBright Absolute Counting Beads Invitrogen Cat# C36950 BD Cytofix/CytopermTM Fixation/Permeabilization Kit BD Biosciences Cat# 554714 Foxp3 / Transcription Factor Staining Buffer Set eBioscience Cat# 00-5523-00 Live/Dead Fixable Near-IR Dead cell stain Kit Invitrogen Cat# L34975 CellTrace Violet Cell Proliferation Kit Invitrogen Cat# C34557 PE Phycoerythrin Fluorescence Quantitation Kit BD Biosciences Cat# 340495 U-PLEX CAR-T Cell Combo 1 (hu) Meso Scale Discovery (MSD) Cat# K15338K V-PLEX Human Proinflammatory Panel I Meso Scale Discovery (MSD) Cat# K15052D V-PLEX Proinflammatory Panel 1 Mouse Kit Meso Scale Discovery (MSD) Cat# K15048D V-PLEX Proinflammatory Panel 1 Human Kit Meso Scale Discovery (MSD) Cat# K15049D RNeasy Mini Kit Qiagen Cat# 74004 SMART-Seq v4 Ultra-low Input RNA Kit for Sequencing Takara Bio Cat# 634890 Nextera XT DNA Library Preparation Kit Illumina Cat# FC-131-1096 Nextera XT Index Set D Illumina Cat# FC-131-2004 AMPure XP beads Beckman Coulter Cat# A63881 Deposited data Bulk RNA-Seq Amgen Inc GEO: GSE264122 Experimental models: Cell lines PL21 https://www.dsmz.de/ Cat# ACC 536 NOMO-1 https://www.dsmz.de/ Cat# ACC 542 MOLM13 https://www.dsmz.de/ Cat# ACC 554 JIMT1 https://www.dsmz.de/ Cat# ACC 589 MC38 ATCC Cat# CRL-2640 B16F10 ATCC Cat# CRL-6475 Experimental models: Organisms/strains B6.129S6-Rag2tm1Fwa N12 (Rag2-/-) Taconic Cat# RAGN12-F C57BL/6N huCD3ε KI Amgen, breeding at CRL N/A NOD.Cg-Prkdcscid IL2Rgtm1Wjl/SzJ; NSG The Jackson Laboratory Strain# 005557 Oligonucleotides CLL1 sgRNA 1 IDT See Table S4 CLL1 sgRNA 2 IDT See Table S4 CLL1 sgRNA 3 IDT See Table S4 HER2 sgRNA 1 IDT See Table S4 HER2 sgRNA 2 IDT See Table S4 HER2 sgRNA 2 IDT See Table S4 NT sgRNA 1 IDT See Table S4 NT sgRNA 2 IDT See Table S4 (Continued on next page) Cell Reports Medicine 6, 102117, May 20, 2025 e3 Article ll OPEN ACCESS

    Techniques: Expressing, Incubation, Lysis, Cell Culture

    Figure 3. Multiple functional NKCEs induce robust killing activity with minimal TNF production (A) Components and designs of multifunctional NKCEs: NKCE-I to NKCE-V. (B–D) NOMO1-Luc cells were incubated with NK cells or Pan T cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-I to NKCE-V and IL-2 or TCE. (B) NOMO1-Luc lysis at 48 h. EC50 and area under curve (AUC) are indicated in the graph. Concentrations of TNF (C) and IFNγ (D) in the cell culture su- pernatants at 48 h. (E) CLL1 expression on PL21-Luc WT and CLL1low. ABC of CLL1 is indicated in the graph. (F–H) PL21-Luc WT or CLL1low cells were incubated with NK cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-III (F), NKCE-IV (G), and NKCE-V (H) and PL21-Luc lysis at 48 h. Data are presented as means ± SEM (B). The data shown are representative of at least two independent experiments.

    Journal: Cell reports. Medicine

    Article Title: Characterization and comparative analysis of multifunctional natural killer cell engagers during antitumor responses.

    doi: 10.1016/j.xcrm.2025.102117

    Figure Lengend Snippet: Figure 3. Multiple functional NKCEs induce robust killing activity with minimal TNF production (A) Components and designs of multifunctional NKCEs: NKCE-I to NKCE-V. (B–D) NOMO1-Luc cells were incubated with NK cells or Pan T cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-I to NKCE-V and IL-2 or TCE. (B) NOMO1-Luc lysis at 48 h. EC50 and area under curve (AUC) are indicated in the graph. Concentrations of TNF (C) and IFNγ (D) in the cell culture su- pernatants at 48 h. (E) CLL1 expression on PL21-Luc WT and CLL1low. ABC of CLL1 is indicated in the graph. (F–H) PL21-Luc WT or CLL1low cells were incubated with NK cells at an E:T cell ratio of 2.5:1 and increasing concentrations of NKCE-III (F), NKCE-IV (G), and NKCE-V (H) and PL21-Luc lysis at 48 h. Data are presented as means ± SEM (B). The data shown are representative of at least two independent experiments.

    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER muCD19 NKCE Amgen Inc In this paper muIgG-IL-2 Amgen Inc In this paper Critical commercial assays EasySepTM Human NK Cell Enrichment Kit STEMCELL Technologies Cat#19055 EasySepTM Human T cell Enrichment Kit STEMCELL Technologies Cat# 19051 EasySepTM Human CD4+ T cell Enrichment Kit STEMCELL Technologies Cat# 19052 EasySepTM Human CD8+ T cell Enrichment Kit STEMCELL Technologies Cat # 19053 Steady-Glo Luciferase Assay System Promega Cat# E2550 CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7573 CountBright Absolute Counting Beads Invitrogen Cat# C36950 BD Cytofix/CytopermTM Fixation/Permeabilization Kit BD Biosciences Cat# 554714 Foxp3 / Transcription Factor Staining Buffer Set eBioscience Cat# 00-5523-00 Live/Dead Fixable Near-IR Dead cell stain Kit Invitrogen Cat# L34975 CellTrace Violet Cell Proliferation Kit Invitrogen Cat# C34557 PE Phycoerythrin Fluorescence Quantitation Kit BD Biosciences Cat# 340495 U-PLEX CAR-T Cell Combo 1 (hu) Meso Scale Discovery (MSD) Cat# K15338K V-PLEX Human Proinflammatory Panel I Meso Scale Discovery (MSD) Cat# K15052D V-PLEX Proinflammatory Panel 1 Mouse Kit Meso Scale Discovery (MSD) Cat# K15048D V-PLEX Proinflammatory Panel 1 Human Kit Meso Scale Discovery (MSD) Cat# K15049D RNeasy Mini Kit Qiagen Cat# 74004 SMART-Seq v4 Ultra-low Input RNA Kit for Sequencing Takara Bio Cat# 634890 Nextera XT DNA Library Preparation Kit Illumina Cat# FC-131-1096 Nextera XT Index Set D Illumina Cat# FC-131-2004 AMPure XP beads Beckman Coulter Cat# A63881 Deposited data Bulk RNA-Seq Amgen Inc GEO: GSE264122 Experimental models: Cell lines PL21 https://www.dsmz.de/ Cat# ACC 536 NOMO-1 https://www.dsmz.de/ Cat# ACC 542 MOLM13 https://www.dsmz.de/ Cat# ACC 554 JIMT1 https://www.dsmz.de/ Cat# ACC 589 MC38 ATCC Cat# CRL-2640 B16F10 ATCC Cat# CRL-6475 Experimental models: Organisms/strains B6.129S6-Rag2tm1Fwa N12 (Rag2-/-) Taconic Cat# RAGN12-F C57BL/6N huCD3ε KI Amgen, breeding at CRL N/A NOD.Cg-Prkdcscid IL2Rgtm1Wjl/SzJ; NSG The Jackson Laboratory Strain# 005557 Oligonucleotides CLL1 sgRNA 1 IDT See Table S4 CLL1 sgRNA 2 IDT See Table S4 CLL1 sgRNA 3 IDT See Table S4 HER2 sgRNA 1 IDT See Table S4 HER2 sgRNA 2 IDT See Table S4 HER2 sgRNA 2 IDT See Table S4 NT sgRNA 1 IDT See Table S4 NT sgRNA 2 IDT See Table S4 (Continued on next page) Cell Reports Medicine 6, 102117, May 20, 2025 e3 Article ll OPEN ACCESS

    Techniques: Functional Assay, Activity Assay, Incubation, Lysis, Cell Culture, Expressing

    Antiproliferative activities of CDDD11-8 against leukemia cell lines having different genetic backgrounds *.

    Journal: Cancers

    Article Title: An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia

    doi: 10.3390/cancers14051113

    Figure Lengend Snippet: Antiproliferative activities of CDDD11-8 against leukemia cell lines having different genetic backgrounds *.

    Article Snippet: MV4-11, HL60, K-562, THP-1, MO91, and U937 cell lines were from the ATCC (Rockville, MD, USA); MOLM-13, NB4, and PL21 cell lines were from the DSMZ (Braunschweig, Germany); and Jurkat cells were from the ECACC (Salisbury, UK).

    Techniques: